Recent highlights

Syntara completes two-tranche placement of A$10m

Syntara completes A$10.0 million via a two-tranche placement at $0.022 per share. The Company completes Share Purchase Plan (SPP) that provided all eligible shareholders the opportunity to participate in the transaction. Funds raised will be used towards completion of three Phase 2 clinical trials in myelofibrosis, scarring and iRBD/Parkinson’s disease as well as for general…

Read more

First patient dosed in Phase 2 bone marrow cancer trial of SNT-5505 in combination with ruxolitinib.

The combination therapy study is recruiting patients from 19 clinical trial sites in Australia, South Korea, Taiwan and the USA. It follows results from an earlier cohort demonstrating SNT-5505 had an excellent safety profile and encouraging signs of efficacy when used in patients who had failed on current standard of care. Watch a Proactive interview…

Read more

Syntara doses first patient in Phase 2 trial of patients with sleep disorder at risk of Parkinson’s disease

Syntara has announced the first patient has been dosed in its randomised double-blind placebo controlled Phase 2 study of the Syntara drug discovery PXS-4728 studying patients with isolated Rapid Eye Movement Sleep Behaviour Disorder (iRBD) who are at risk of Parkinson’s disease. The study will examine whether targeting inflammation in the brain of people with…

Read more

Sale of mannitol respiratory business and launch of Syntara

Pharmaxis has announced details of the sale of its mannitol respiratory business which manufactures and supplies Aridol and Bronchitol to global markets and the formation of Syntara, a clinical stage drug development company primarily focusing on treatments for haematological malignancies (blood-related cancers). In a major restructure the mannitol business will be sold to pharmaceutical manufacturing…

Read more

Publication in Nature Cancer

The prestigious journal Nature Cancer has published preclinical results showing Pharmaxis’ pan-Lysyl Oxidase (pan-LOX) inhibitor PXS-5505 increases survival by 35% compared to chemotherapy treatment alone in the treatment of pancreatic ductal adenocarcinomas. Research in mouse models, led by a team at the Garvan Institute of Medical Research also showed PXS-5505 combined with chemotherapy reduced the…

Read more

Pharmaxis achieves 30% reduction in scar tissue in topical LOX inhibitor in Phase 1C study; extends collaboration with UWA

Pharmaxis’ novel topical drug treatment for scarring has achieved encouraging results from a phase 1c showing marked change in scar composition with 30% reduction in collagen content. The study of LOX inhibitor PXS-6302 is being conducted by the University of Western Australia (UWA) under the leadership of Professor Fiona Wood AM.  The study aims to…

Read more